Cocrystal Pharma
Update in progressCOCP (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cocrystal Pharma, Inc. is a Bothell, Washington–based biotechnology company focused on antiviral therapies for serious and chronic viral diseases in the United States. Using structure-based design, it targets influenza A/B, coronaviruses (including SARS-CoV-2 and MERS), norovirus, other respiratory viruses, and hepatitis C. It develops CC-42344, a PB2 inhibitor in phase 2a, and an inhaled form for flu prophylaxis; CDI-988 (pan-viral) in phase 1; and CC-31244 for HCV in phase 2a. It licenses influenza programs from Merck and antiviral work from Kansas State University. Founded 2006.
Company score
- Sentiment
- 0.27
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Sam Lee Ph.D.
- Founded2006
- Employees10
- Websitewww.cocrystalpharma.com
Identifiers
- ISINUS19188J4094
- FIGIBBG000V27360
- CUSIP09072E103
- CIK0001412486